<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Dietary recommendations for patients with nondialysis chronic kidney disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Dietary recommendations for patients with nondialysis chronic kidney disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Dietary recommendations for patients with nondialysis chronic kidney disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Monique E Cho, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Srinivasan Beddhu, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gary C Curhan, MD, ScD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 28, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1193187386">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic kidney disease (CKD) is common in the United States and worldwide. CKD patients have a higher mortality than the general population [
         <a href="#rid1">
          1
         </a>
         ]. Mortality is related in part to the progression of kidney disease and its complications, such as cardiovascular disease (CVD) and protein-energy wasting.
        </p>
        <p>
         Dietary factors may have an effect on the progression of kidney disease and its complications. Among CKD patients, overnutrition results in sodium and volume overload, hyperkalemia, hyperphosphatemia, and accumulation of toxic metabolites of protein degradation. Undernutrition, on the other hand, exacerbates the risk for malnutrition and wasting.
        </p>
        <p>
         Appropriate dietary interventions may have an effect on clinical outcomes in the CKD population. However, the optimal approach to nutrition is not known with certainty, and clinical trials have yielded conflicting results.
        </p>
        <p>
         This topic review provides recommendations for nutrition for predialysis CKD patients. Recommendations for nutrition in the general public are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5366.html" rel="external">
          "Dietary assessment in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3016.html" rel="external">
          "Geriatric nutrition: Nutritional issues in older adults"
         </a>
         .)
        </p>
        <p>
         The approach to nutrition in dialysis patients is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1850.html" rel="external">
          "Assessment of nutritional status in patients on hemodialysis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1855.html" rel="external">
          "Nutritional status and protein intake in patients on peritoneal dialysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1107315160">
         <span class="h1">
          OVERVIEW
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal diet for individual CKD patients varies depending upon the estimated glomerular filtration rate (eGFR), type of kidney disease (ie, proteinuric or nonproteinuric), and the presence of other comorbidities such as diabetes, hypertension, or heart failure. For most CKD patients, the optimal diet is one similar to the Dietary Approaches to Stop Hypertension (DASH) diet, which is low in sodium content and rich in fruits, vegetables, legumes, fish, poultry, and whole grains. (See
         <a class="medical medical_review" href="/z/d/html/3878.html" rel="external">
          "Diet in the treatment and prevention of hypertension", section on 'Dietary Approaches to Stop Hypertension (DASH) diet'
         </a>
         .)
        </p>
        <p>
         However, among many patients, the diet needs to be modified further depending on specific laboratory values including serum potassium or serum phosphorus.
        </p>
        <p>
         We do not suggest any dietary modification for patients with eGFR ≥60 mL/min/1.73 m
         <sup>
          2
         </sup>
         . Such patients should follow the same dietary recommendations as for the general population. (See
         <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">
          "Healthy diet in adults"
         </a>
         .)
        </p>
        <p>
         We suggest the following dietary guidelines for most patients with eGFR &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         who are not on dialysis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A daily protein intake of 0.8 g/kg. We do not recommend very low-protein intake (&lt;0.6 g/kg/day).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A diet rich in vegetables.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The sodium intake varies depending on individual patient clinical features. Among individuals who are hypertensive, volume overloaded, or proteinuric, we suggest a sodium intake of &lt;2 g/day (ie, 5 g/day of salt [NaCl]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who are not hypertensive, volume overloaded, or proteinuric, sodium restriction to 2.3 g/day (5.75 g/day of salt [NaCl]) may be of benefit. There are no convincing studies of the general population that have proven that lowering sodium intake to &lt;2.3 g/day lowers cardiovascular outcomes or all-cause mortality. The Institute of Medicine has concluded that there is insufficient evidence to recommend a different sodium intake for CKD patients as compared with the general United States population [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The potassium intake should be guided by serum potassium levels. If the potassium concentration is normal, we do not restrict dietary potassium. If the potassium concentration is high, dietary potassium intake should be restricted. (See
         <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">
          "Treatment and prevention of hyperkalemia in adults", section on 'Prevention'
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/4427.html" rel="external">
          "Patient education: Low-potassium diet (Beyond the Basics)", section on 'How do I cut down on potassium?'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some clinicians target a total calcium intake (both dietary and medication sources) ≤1500 mg/day, whereas others prefer a more stringent goal of ≤1000 mg/day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maximum phosphorus intake of 0.8 to 1 g/day, even if the serum phosphorus concentration is normal; this is because some studies suggest that dietary phosphorus intake may alter circulating fibroblast growth factor (FGF) 23 concentrations (see
         <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">
          "Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Fibroblast growth factor 23'
         </a>
         ). The dietary phosphorus should be derived from sources of high biologic value, such as meats and eggs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maximum caloric intake of 25 to 35 kcal/kg/day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maximum fat intake &lt;30 percent of daily energy intake, with saturated fat limited to &lt;10 percent energy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Daily dietary fiber intake of 25 to 34 g/day.
        </p>
        <p>
        </p>
        <p>
         These recommendations, along with supporting studies, are individually discussed below.
        </p>
        <p class="headingAnchor" id="H1107315266">
         <span class="h1">
          PROTEIN INTAKE
         </span>
        </p>
        <p class="headingAnchor" id="H1193190287">
         <span class="h2">
          Non-nephrotic patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         who do not have nephrotic syndrome, we suggest restricting daily protein intake to 0.8 g/kg. Nutritional studies in patients with reduced eGFR suggest that protein intake can be safely lowered to 0.6 g/kg/day [
         <a href="#rid3">
          3-7
         </a>
         ] although a very low-protein diet has been associated with increased mortality over the long term [
         <a href="#rid8">
          8
         </a>
         ]. A modest restriction is generally well tolerated and does not lead to malnutrition in patients with CKD, and metabolic acidosis is avoided.
        </p>
        <p>
         Most clinical guidelines, including Kidney Disease: Improving Global Outcomes (KDIGO) and the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI), suggest restriction of protein intake for CKD patients [
         <a href="#rid9">
          9,10
         </a>
         ].
        </p>
        <p>
         Studies that have examined protein restriction have yielded inconsistent results [
         <a href="#rid11">
          11-17
         </a>
         ].
        </p>
        <p>
         Many early studies suggested that protein restriction may slow progression of CKD [
         <a href="#rid16">
          16,18-23
         </a>
         ] although subsequent rigorous studies suggest that the benefit is modest [
         <a href="#rid8">
          8,13,16,17,23-29
         </a>
         ]. The largest trial to date, the Modification of Diet in Renal Disease (MDRD) study, analyzed 585 patients with nondiabetic CKD and a mean GFR of 39 mL/min/1.73 m
         <sup>
          2
         </sup>
         (all patients with GFR &lt;55 mL/min/1.73 m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid26">
          26
         </a>
         ]. Patients were randomly assigned to protein intakes of 1.3 or 0.58 g/kg/day with or without aggressive blood pressure (BP) control and followed for a mean of 2.2 years. The mean achieved protein intake was 1.11 g/kg/day for the usual-protein-diet group and 0.77 g/kg/day (approximately 45 to 60 g/day) for the low-protein-diet group [
         <a href="#rid12">
          12
         </a>
         ]. This level of protein intake is substantially below the average protein intake in the United States of 90 to 100 g/day.
        </p>
        <p>
         Despite good adherence, initially, there appeared to be little overall benefit with the low-protein diet. A biphasic response was noted: Patients treated with protein restriction had a greater fall in GFR (measured by iothalamate clearance) in the first four months (that may have reflected a reduction in intraglomerular pressure), followed by somewhat slower progression over the ensuing months (2.8 versus 3.9 mL/min/year)  (
         <a class="graphic graphic_figure graphicRef59277" href="/z/d/graphic/59277.html" rel="external">
          figure 1
         </a>
         ). Interpretation of the MDRD trial is somewhat limited by this since the trial design did not account for this two-slope change in GFR in the moderate-protein-intake group. However, even in the later phase, the absolute benefit was approximately 1.1 mL/min/year. A similar lack of substantial benefit was noted in a second part of this study involving 255 patients with more advanced disease (mean GFR 19 mL/min/1.73 m
         <sup>
          2
         </sup>
         ) who were randomly assigned to a low-protein diet (0.58 g/kg/day) or a very low-protein diet (0.3 g/kg/day) with a keto acid-amino acid supplement.
        </p>
        <p>
         Other limitations to the trial are that it included very few diabetic patients (patients with insulin-requiring diabetes were excluded) and the rate of decline in GFR in the intervention and control groups was slower than expected, which may have resulted in decreased power to discern potential benefit. As the curves diverged at the end of the study, there is a possibility that longer-term follow-up of these patients would have revealed a slower progression in the moderate-protein-intake group.
        </p>
        <p>
         A benefit of moderate protein restriction was suggested by a long-term follow-up analysis of the MDRD study, which was performed by linking the MDRD study to national registries [
         <a href="#rid27">
          27
         </a>
         ]. In this 12-year study (1989 to 2000), the authors evaluated outcomes during the first six years after the trial ended (1989 to 1994), the next six-year period (1995 to 2000), and the total 12-year period. Analysis of outcomes after the first six years revealed a significant benefit of low-protein intake on kidney failure and all-cause mortality (hazard ratios [HRs] 0.68, CI 0.51-0.93 and 0.66, CI 0.50-0.87, respectively). However, there was no benefit of protein restriction when outcomes between 6 and 12 years were analyzed, but protein intake data were not available following the completion of the randomized study phase. Thus, it is possible that the early beneficial effects in the first six years dissipated after six years because the study participants were no longer on the intervention.
        </p>
        <p>
         These data suggest the need for a longer follow-up period for future studies designed to assess the effects of protein restriction intervention. In the MDRD study, the average rate of GFR decline was 4 mL/min/1.73 m
         <sup>
          2
         </sup>
         per year during the mean duration of 2.2 years, and relatively few patients developed kidney failure during this period. It is possible that the study duration was too short to fully appreciate the effect of protein restriction.
        </p>
        <p>
         Since the initial MDRD report in 1994, several secondary analyses of the MDRD study, as well as other meta-analyses and controlled trials, have been published [
         <a href="#rid11">
          11,12
         </a>
         ]. Systematic reviews suggest that protein restriction may be beneficial [
         <a href="#rid30">
          30-34
         </a>
         ]. As an example, a Cochrane review limited to studies that used kidney death as an outcome measure (n = 10) demonstrated a protective effect of protein restriction despite heterogeneity among studies [
         <a href="#rid30">
          30
         </a>
         ]. Kidney death in this review was defined as the need for starting dialysis, the death of the patient, or a kidney transplant. This analysis suggested that protein restriction decreases the number of patients reaching the defined outcome by approximately 32 percent. This equates to treating 2 to 56 patients with a low-protein diet to avoid one kidney death.
        </p>
        <p>
         Overall, most experts believe that, despite the absence of observed benefit in the MDRD trial, the balance of evidence suggests a benefit of moderate dietary protein restriction [
         <a href="#rid11">
          11,12
         </a>
         ]. Some of the MDRD investigators have proposed that the seemingly small benefit from protein restriction may be clinically important [
         <a href="#rid12">
          12
         </a>
         ]. According to this reasoning, a patient with a GFR of 40 mL/min who is losing 4 mL/min per year will require dialysis in approximately eight years. However, if the rate of fall were only 3 mL/min per year, then 11 years would be required to reach the same endpoint. Thus, the absolute benefit would be three years without dialysis.
        </p>
        <p>
         In addition, protein restriction may be particularly effective in diseases characterized by hyperfiltration, such as diabetes and certain glomerulopathies [
         <a href="#rid16">
          16,21,22
         </a>
         ], although one study has suggested that the effects of protein restriction in advanced kidney disease due to polycystic kidney are similar to that due to other causes [
         <a href="#rid12">
          12
         </a>
         ]. Polycystic kidney disease (PKD) is not characterized by hyperfiltration and tends to have a very different rate of progression compared with diabetic and other glomerulopathies.
        </p>
        <p>
         Limiting protein intake is also associated with favorable laboratory and metabolic effects, including reduction of blood urea nitrogen levels, uremic toxins, and acid load, in addition to reduced phosphorus load with better control of metabolic bone disorders [
         <a href="#rid35">
          35
         </a>
         ]. A modest protein restriction to 0.6 to 0.8 g/kg/day appears to be safe. The safety profile of a modest protein restriction was assessed in an analysis of patients who were enrolled in the MDRD study [
         <a href="#rid4">
          4
         </a>
         ]. Patients were randomly assigned to a standard-protein diet (1.3 g/kg/day), a low-protein diet (0.58 g/kg/day), or a very low-protein diet (0.3 g/kg/day supplemented with a ketoacid-amino acid mixture at 0.28 g/kg/day) based upon their GFR. Patients assigned to the low-protein diet achieved a protein intake between 0.6 to 0.8 g/kg/day. Patients assigned to the very low-protein diet achieved a protein intake between 0.4 to 0.8 g/kg/day.
        </p>
        <p>
         At a mean follow-up of 2.2 years, a low-protein intake was not associated with increased rates of mortality, hospitalization, or malnutrition.
        </p>
        <p>
         We do not recommend very low-protein intake (&lt;0.6 g/kg/day) in CKD patients due to the safety concerns. Significant health risks are associated with more severe restrictions over the long term. The MDRD study tested the effects of low-protein diet (0.58 g/kg/day) or a very low-protein diet (0.28 g/kg/day) with a keto acid-amino acid supplement in those with GFR between 13 to 24 mL/min/1.73 m
         <sup>
          2
         </sup>
         on death/end-stage kidney disease (ESKD) outcome. While there were no statistically significant differences between the two groups during the trial, a longer-term, postintervention, observational follow-up showed a higher risk of death in those assigned to the very low-protein group (HR 1.92, 95% CI 1.15-3.20) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         An important limitation of these long-term observations is that measurements of protein intake or nutritional measurements were not performed beyond nine months after the original MDRD study ended; the number of patients that continued the prescribed diet is not known [
         <a href="#rid36">
          36
         </a>
         ]. Despite this limitation, these observations suggest that important long-term safety risks are associated with the very low-protein diet among patients with advanced CKD.
        </p>
        <p>
         Our recommendation varies somewhat from the 2020 National Kidney Foundation KDOQI guidelines, which suggest a low-protein diet (0.55 to 0.6 g/kg/day) or very low-protein diet (0.28 to 0.43 g/kg/day with keto acid/amino acid analogs supplementation) in nondiabetic adults with stage 3 to 5 CKD who are metabolically stable [
         <a href="#rid10">
          10,16,17
         </a>
         ].
        </p>
        <p>
         Patients with CKD who are on a protein-restricted diet should be carefully monitored, with close follow-up every three to six months for adequate caloric intake and evidence of protein malnutrition. We usually follow the body weight as well as serum albumin.
        </p>
        <p>
         Three conditions must be met to avoid malnutrition:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adequate caloric intake must be maintained (by increasing polyunsaturated fats and by avoiding processed carbohydrates).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least 60 percent of the ingested protein must be of high biologic value or contain a high percentage of essential amino acids  (
         <a class="graphic graphic_table graphicRef67821" href="/z/d/graphic/67821.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stimulation of skeletal muscle protein breakdown should be prevented to limit net nitrogen loss. Metabolic acidosis should be treated since metabolic acidosis stimulates skeletal muscle protein breakdown [
         <a href="#rid3">
          3,37
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/2293.html" rel="external">
          "Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease"
         </a>
         ). A protein-restricted diet may, of itself, help to prevent metabolic acidosis. A post-hoc analysis of the MDRD study showed that a reduction in protein intake resulted in increased serum CO
         <sub>
          2
         </sub>
         after one year of follow-up [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1193190281">
         <span class="h2">
          Patients with nephrotic syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not restrict protein intake among patients with nephrotic syndrome. The safety of a low-protein diet in nephrotic syndrome is uncertain. In some experimental models of nephrotic syndrome, the institution of a low-protein diet diminished hepatic albumin synthesis, which suggests protein deficiency [
         <a href="#rid39">
          39,40
         </a>
         ]. However, in the same study, a low-protein diet also decreased protein excretion, presumably due to a fall in intraglomerular pressure. The net effect of these opposing factors was no change in the plasma albumin concentration [
         <a href="#rid39">
          39,40
         </a>
         ]. Overall, studies have not demonstrated conclusive evidence of malnutrition with protein restriction in moderately nephrotic animals [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         One study examined this issue in five stable patients with nephrotic syndrome [
         <a href="#rid42">
          42
         </a>
         ]. Despite moderate proteinuria that averaged 7.2 g/day, nitrogen balance was maintained on a diet that provided 0.8 g/kg/day of protein plus 1 g of protein for each gram of proteinuria and 35 kcal/kg/day. Positive nitrogen balance was maintained by the inhibition of amino acid oxidation and protein degradation and by stimulation of protein synthesis during feeding.
        </p>
        <p>
         These data suggest that protein restriction can be safely implemented in patients with moderate proteinuria, providing adequate caloric intake is maintained. However, these data do not define the minimum safe protein intake, nor do they prove that supplementing protein intake for the degree of proteinuria is necessary. In addition, the safety of protein restriction in patients with massive proteinuria (&gt;15 g/day) or concurrent catabolic states (eg, due to corticosteroids or systemic lupus erythematosus) is uncertain, even with adequate caloric intake.
        </p>
        <p class="headingAnchor" id="H712938688">
         <span class="h2">
          Source of protein intake
         </span>
         <span class="headingEndMark">
          —
         </span>
         A diet rich in protein from plant sources may be beneficial among CKD patients. Observational data suggest that such a diet may reduce proteinuria [
         <a href="#rid43">
          43-45
         </a>
         ], lower the incidence and slow the progression of CKD [
         <a href="#rid45">
          45-52
         </a>
         ], decrease the production of uremic toxins [
         <a href="#rid53">
          53-58
         </a>
         ], lower phosphorus intake, lower the endogenous production of acid [
         <a href="#rid48">
          48,49,59,60
         </a>
         ], and potentially decrease mortality risk [
         <a href="#rid61">
          61-63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2293.html" rel="external">
          "Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease", section on 'Choice of therapy'
         </a>
         .)
        </p>
        <p>
         A randomized trial compared a very low plant-based protein diet (0.3 g/kg/day) supplemented with ketoanalogues (KD) with a mixed-source (plant- and animal-based) low-protein diet (0.6 g/kg/day) among 207 patients with a stable eGFR &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         [
         <a href="#rid47">
          47
         </a>
         ]. The median achieved protein intake was 0.29 and 0.59 g/kg/day in the KD and low-protein diet groups, respectively. At 18 months of follow-up, compared with the low-protein diet group, fewer patients in the KD group reached the composite endpoint of &gt;50 percent reduction in eGFR or initiation of kidney replacement therapy (KRT; 42 versus 13 percent, respectively). Compared with the low-protein diet group, fewer patients in the KD group required KRT (30 versus 11 percent).
        </p>
        <p>
         However, caution is warranted in interpreting these results. While there were no differences between groups in anthropometric or biochemical parameters of nutrition during the duration of this study, in the long-term follow-up of the MDRD study, there was increased mortality among those randomized to a very low-protein diet (0.28 g/kg/day supplemented with a mixture of essential keto acids and amino acids) compared with a low-protein diet (0.58 g/kg/day) [
         <a href="#rid8">
          8
         </a>
         ] (see
         <a class="local">
          'Non-nephrotic patients'
         </a>
         above). Long-term studies of very low plant protein diets that examine mortality as a predefined outcome are warranted.
        </p>
        <p>
         Concerns have also been raised about delayed registration of this trial in the public trials registry until after enrollment of some participants.
        </p>
        <p>
         Studies that compare protein sources but maintain comparable levels of moderate protein intake (0.6 to 0.8 g/day) are required before a recommendation could be made for a primarily plant-based source of dietary protein.
        </p>
        <p class="headingAnchor" id="H712938695">
         <span class="h1">
          SALT INTAKE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Salt is nutritionally equivalent to sodium chloride: 1 g salt of contains 0.4 g (17 mEq) of Na ion. Understanding these units is important for making dietary recommendations to patients.
        </p>
        <p>
         Among selected CKD patients with estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         who have hypertension, volume overload, or increased protein excretion, we suggest a sodium intake of &lt;2 g/day (5 g/day of salt).
        </p>
        <p>
         The approach for patients with reduced eGFR who do NOT have hypertension, volume overload, or increased protein excretion is not clear. For most patients, we generally advise a mild sodium restriction of 2.3 g/day (5.75 g/day of salt [NaCl]). An exception is the occasional CKD patient who wastes sodium.
        </p>
        <p>
         We suggest not reducing sodium to &lt;1500 mg/day (ie, salt &lt;3 g/day). We agree with the conclusion of the US Centers for Disease Control and Prevention-commissioned Institute of Medicine Committee that there is insufficient evidence to recommend sodium restriction to ≤1500 mg/day in high-risk groups (ie, including CKD patients) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         In addition, very low sodium intake has been associated with increased mortality. In the Prospective Urban Rural Epidemiology (PURE) study of 101,945 people in 17 countries, compared with the reference range of estimated sodium excretion of 4 to 5.99 g/day, an estimated sodium excretion that was below 3 g/day was associated with an increased risk of the composite outcome of death or cardiovascular event (odds ratio [OR] 1.27, 95% CI 1.12-1.44). In the same study, very high Na intake above 6 g/day was associated with 15 percent higher risk of death or cardiovascular event [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         It is unlikely that a large, randomized, controlled trial to conclusively establish the effects of Na intake on cardiovascular mortality and all-cause mortality will ever be conducted.
        </p>
        <p>
         Our recommendation for a modest sodium restriction is consistent with the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for the management of CKD [
         <a href="#rid9">
          9
         </a>
         ], the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) 2020 guidelines [
         <a href="#rid10">
          10
         </a>
         ], and the U.S. Department of Agriculture and U.S. Department of Health and Human Services Dietary Guidelines for Americans 2020-2025 [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         Among CKD patients, the benefits of salt restriction might include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lower blood pressure (BP)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Slower progression to end-stage kidney disease (ESKD)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improved cardiovascular outcomes
        </p>
        <p>
        </p>
        <p>
         These are discussed separately below.
        </p>
        <p class="headingAnchor" id="H1193190723">
         <span class="h2">
          Hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Large, long-term, randomized, controlled trials that assess the efficacy and safety of salt restriction in the CKD population are largely absent. The guidelines for dietary sodium intake in CKD, therefore, are based on expert opinion, observational studies, and extrapolation from general population studies. Studies overall suggest that salt restriction reduces the risk of hypertension in the general population. (See
         <a class="medical medical_review" href="/z/d/html/3877.html" rel="external">
          "Salt intake and hypertension"
         </a>
         .)
        </p>
        <p>
         A moderate salt restriction also reduces the risk of hypertension among CKD patients in small studies [
         <a href="#rid66">
          66-70
         </a>
         ]. A four-week randomized crossover of dietary sodium restriction (target &lt;2 g/day versus usual diet) in stage 3 to 4 CKD resulted in a significant reduction in systolic BP (-10.8 mmHg; 95% CI -17 to -4.6) [
         <a href="#rid68">
          68
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3872.html" rel="external">
          "Overview of hypertension in acute and chronic kidney disease", section on 'Benefits of sodium restriction'
         </a>
         .)
        </p>
        <p>
         However, in a six-month trial comparing self-management support plus standard care with standard care alone, differences in sodium excretion rates and ambulatory blood pressures between the groups at six months were not different, illustrating the difficulties in sustained sodium restriction [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1193190730">
         <span class="h2">
          CKD progression
         </span>
         <span class="headingEndMark">
          —
         </span>
         Very few studies have examined the effect of salt restriction on CKD progression. The limited available data suggest both direct and indirect benefit of sodium restriction on CKD outcomes, mostly regarding its synergistic effect to lower proteinuria in the setting of renin-angiotensin system inhibition:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A post-hoc analysis of the first and second
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          Ramipril
         </a>
         Efficacy in Nephropathy (REIN) trials suggested a potential benefit of sodium restriction [
         <a href="#rid71">
          71
         </a>
         ]. During four years of follow-up, compared with those with a low-salt intake (&lt;100 mEq/g urinary sodium/creatinine excretion), the risk of progression to ESKD was greater in those with high-salt intake (≥200 mEq/g urinary excretion; 6.1 versus 18.2 per 100 patient-years). A 100 mEq/g higher urinary sodium/creatinine excretion ratio was associated with a 40 percent increase in the risk of ESKD regardless of baseline proteinuria and other risk factors. However, the association between salt intake and the risk of ESKD disappeared after adjustment for changes in proteinuria, suggesting that, in CKD patients treated by angiotensin-converting enzyme (ACE) inhibitors, the increase in proteinuria is a primary mechanism by which high-sodium intake accelerates the progression of CKD toward ESKD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a post-hoc analysis of the HALT-PKD trial, lower urinary sodium excretion was significantly associated with decreased kidney growth in those with eGFR &gt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         . In polycystic kidney disease (PKD) patients with eGFR 25 to 60 mL/min/1.73 m
         <sup>
          2
         </sup>
         , urinary sodium excretion was significantly associated with increased risk for the composite endpoint of 50 percent reduction in eGFR, ESKD, or death (HR 1.08 for each 18 mEq urinary sodium excretion) and faster eGFR decline rate (-0.09 mL/min/1.73 m
         <sup>
          2
         </sup>
         /year for each 18 mEq urinary sodium excretion) [
         <a href="#rid72">
          72
         </a>
         ]. Sodium restriction, therefore, is beneficial in the management of autosomal dominant PKD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Chronic Renal Insufficiency Cohort (CRIC) study, compared with the lowest quartile of urinary sodium excretion (&lt;117 mmol/24 hours), hazard ratios for the highest quartile of urinary sodium excretion (&gt;195 mmol/24 hours) were 1.54 (95% CI, 1.23-1.92) for CKD progression, 1.45 (95% CI, 1.08-1.95) for all-cause mortality, and 1.43 (95% CI, 1.18-1.73) for the composite outcome of CKD progression and all-cause mortality [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         However, despite these benefits, there are concerns that excessive lowering of sodium intake may adversely affect neurohormonal balance and lipids and generate proinflammatory milieu, which could enhance progression of disease among CKD patients [
         <a href="#rid74">
          74
         </a>
         ]. A meta-analysis suggested that salt restriction increases plasma levels of renin, aldosterone, catecholamines, and lipids [
         <a href="#rid75">
          75
         </a>
         ]. When salt intake is reduced, a fall in extravascular volume stimulates the renin-angiotensin-aldosterone axis and sympathetic system. These physiologic compensatory responses are more pronounced with sudden and large reduction in salt intake but become minimal with chronic, modest salt reduction. Nonetheless, it has been argued that these are only short-term responses, and, in the longer term, modest salt restriction over weeks results in only small increases in plasma levels of renin, aldosterone, and catecholamines, without any effect on the lipids [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H712938887">
         <span class="h2">
          Cardiovascular disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The effect of salt restriction on cardiovascular outcomes has been difficult to ascertain definitively due to feasibility and logistic challenges. Evaluating cardiovascular morbidity and mortality requires a large sample size with extended follow-up. In addition, participants randomized to low-salt intake typically return to regular salt intake once the trial intervention phase ends, further limiting the ability to accurately assess the effect of long-term salt restriction.
        </p>
        <p>
         Suggestive evidence for the cardiovascular protective effect of salt restriction in the general population is provided by the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of observational studies suggests that a 5 g/day higher salt intake is associated with a 23 percent increase in stroke risk and a 17 percent increase in cardiovascular disease (CVD) [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An observational 10- to 15-year follow-up study of Trials of Hypertension Prevention (TOHP I and II) demonstrated that net sodium restriction of 33 to 44 mmol/day (0.75 to 1 g/day) in the intervention arm resulted in a 30 percent reduction lower cardiovascular event after adjustment for baseline sodium excretion and weight [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an analysis of the CRIC study of CKD participants, adjusted hazard ratios of the highest as compared with the lowest quartile of sodium intake were 1.36 (95% CI, 1.09-1.70) for composite CVD events, 1.34 (95% CI, 1.03-1.74) for heart failure, and 1.81 (95% CI, 1.08-3.02) for stroke [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H712938904">
         <span class="h1">
          POTASSIUM INTAKE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dietary potassium intake should be individualized based on the serum potassium. In general, potassium restriction is not required until the estimated glomerular filtration rate (eGFR) decreases to &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         . However, there is variability between patients, and some patients with higher eGFRs and who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) will require potassium restriction to maintain a normal serum potassium.
        </p>
        <p>
         The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guideline recommends potassium intake between 2 to 4 g/day (51 to 102 mEq/day) for patients with CKD stages 3 to 4 (ie, eGFR 30 to 59 mL/min/1.73 m
         <sup>
          2
         </sup>
         ), while recommending no restriction for those in earlier stages of CKD. However, we believe that dietary potassium recommendations need to be individually tailored based on the level of eGFR and serum potassium levels.
        </p>
        <p>
         Our individualized approach towards potassium restriction among patients with CKD is based upon the beneficial effects of a normal to high potassium diet, which have been demonstrated in observational studies in the general population and in patients with CKD. Consumption of a potassium-rich diet is associated with a lower risk of incident CKD in the patients with normal kidney function and a slower decline in eGFR among patients with CKD [
         <a href="#rid45">
          45,80
         </a>
         ]. Other benefits of high dietary potassium intake in the general population include a reduction in systolic BP [
         <a href="#rid81">
          81-83
         </a>
         ], a lower risk of stroke, and higher bone mineral density [
         <a href="#rid84">
          84-87
         </a>
         ].
        </p>
        <p>
         However, the associations of potassium intake with CKD progression and mortality in CKD are controversial; a report from the Chronic Renal Insufficiency Cohort (CRIC) study observed a higher risk of CKD progression but not all-cause mortality with higher potassium intake [
         <a href="#rid73">
          73
         </a>
         ]. Conversely, analyses of the Modification of Diet in Renal Disease (MDRD) cohort suggested that higher potassium consumption was associated with lower risk of all-cause mortality but not kidney failure [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H712938911">
         <span class="h1">
          CALCIUM INTAKE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some clinicians target a total calcium intake (both dietary and medication sources) ≤1500 mg/day whereas others prefer a more stringent goal of ≤1000 mg/day. The Kidney Disease Outcomes Quality Initiative (KDOQI) guideline (2020) suggests limiting total calcium intake (both dietary and medication sources) to 800 to 1000 mg/day for adults with CKD stage 3 to 4 not taking active vitamin D analogs [
         <a href="#rid10">
          10,89
         </a>
         ]. The Dietary Guidelines for Americans 2020-2025 recommend a dietary calcium goal of 1000 mg/day in adults [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         Calcium supplementation of 2 to 4 g/day results in suppression of parathyroid hormone levels in advanced CKD [
         <a href="#rid90">
          90
         </a>
         ]. Administration of calcium-containing phosphorus binders in hemodialysis patients, however, results in increased vascular calcification [
         <a href="#rid91">
          91
         </a>
         ], raising concerns about the safety of higher calcium intake in predialysis patients.
        </p>
        <p>
         There are no randomized, controlled trials that established the safe levels of calcium intake in predialysis CKD.
        </p>
        <p>
         However, in a calcium balance study, both normal individuals and patients with late-stage 3 and stage 4 CKD were in slightly negative to neutral calcium balance on an 800 mg calcium diet [
         <a href="#rid92">
          92
         </a>
         ]. Normal individuals were in modest positive calcium balance on the 2000 mg diet, while patients with CKD on the same diet were in marked positive calcium balance. Furthermore, increased calcium intake significantly decreased 1,25-dihydroxy-vitamin D and intact parathyroid hormone levels but did not alter the serum calcium concentration.
        </p>
        <p>
         These data suggest that a diet of 2000 mg/day of calcium in CKD patients might result in a positive calcium balance, with the extra calcium deposited in tissues, leading to metastatic calcification.
        </p>
        <p class="headingAnchor" id="H712938918">
         <span class="h1">
          PHOSPHORUS INTAKE
         </span>
         <span class="headingEndMark">
          —
         </span>
         We restrict dietary phosphorus intake to a maximum of 0.8 to 1 g/day or modify the phosphorous intake to normalize the serum level in patients with an estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         ,
         <sup>
         </sup>
         although it is not clear that dietary restriction significantly alters the serum phosphate concentration among nondialysis CKD patients [
         <a href="#rid9">
          9,89,93-95
         </a>
         ]. We do not restrict dietary phosphorus intake in CKD patients who have normal serum phosphate levels and parathyroid hormone (PTH) values. The management of hyperphosphatemia and secondary hyperparathyroidism is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1942.html" rel="external">
          "Management of hyperphosphatemia in adults with chronic kidney disease", section on 'Phosphate restriction'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">
          "Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease", section on 'Initial treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">
          "Management of secondary hyperparathyroidism in adult patients on dialysis", section on 'Treat hyperphosphatemia'
         </a>
         .)
        </p>
        <p>
         The average phosphorus intake in the United States population is 1300 mg/day. For healthy adults, Dietary Guidelines for Americans 2020-2025 recommend intake of 700 mg/day of phosphorus [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         Higher serum phosphorus concentrations have been associated with increased cardiovascular risk, both in the general and CKD populations [
         <a href="#rid96">
          96-98
         </a>
         ]. The association between serum phosphorus levels and cardiovascular risk is independent of eGFR and other cardiovascular disease (CVD) risk factors, even at modestly increased phosphorus concentrations.
        </p>
        <p>
         A large meta-analysis of 14 studies showed an 18 percent risk of death for every 1 mg/dL increase in serum phosphorus (95% CI 1.12-1.25) in the CKD population [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
         Possible mechanisms underlying the increased cardiovascular risk include accelerated vascular calcification and arterial stiffness and induction of fibroblast growth factor (FGF) 23, which has been implicated in the development of left ventricular hypertrophy [
         <a href="#rid99">
          99
         </a>
         ]. FGF-23 is also associated with increased risk of coronary heart disease, heart failure, and cardiovascular mortality independent of traditional cardiovascular risk factors and kidney function [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
         Because inorganic phosphate has much higher bioavailability compared with organic phosphate, sources rich in inorganic phosphate such as highly processed foods should be avoided as much as possible. Organic phosphate (ie, from unprocessed foods) must be hydrolyzed enzymatically in the gut before it can be absorbed. By contrast, foods that are highly concentrated in readily absorbable inorganic phosphate, such as preservatives used in processed and precooked meals, result in much greater absorption of phosphorus.
        </p>
        <p>
         Dietary phosphate load is closely related to protein content. As noted above, using plant sources of protein may be beneficial for controlling phosphorus load (see
         <a class="local">
          'Source of protein intake'
         </a>
         above). Plant sources have the lowest bioavailability of phosphorus, with grains yielding only 50 percent bioavailability of phosphorus [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
         However, unlike the dialysis population, in nondialysis CKD patients with eGFR &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         , the effect of dietary phosphorus restriction on the serum level is limited.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A small, crossover study in eight patients with a mean eGFR of 32 mL/min/1.73 m
         <sup>
          2
         </sup>
         demonstrated that allocation to a vegetarian protein source to reduce absorbable phosphorus led to only a mild reduction in serum phosphorus (0.3 mg/dL) [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several randomized trials, including the Modification of Diet in Renal Disease (MDRD) study, did not show statistically significant reduction in the serum phosphorus concentration despite significant reduction in urinary phosphorus excretion by the use of oral phosphorus binders [
         <a href="#rid102">
          102,103
         </a>
         ] or protein restriction [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This may relate to the fact that the studies relied on the morning fasting sample for phosphorus measurement, which may be less associated with dietary phosphorus absorption than afternoon measurements [
         <a href="#rid105">
          105
         </a>
         ]. Morning fasting levels remain stable despite a wide fluctuation in dietary phosphorus absorption, making the morning value an insensitive marker for phosphorus overload.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is possible that dietary protein restriction or use of phosphorus binders may reduce afternoon serum phosphorus levels; it remains unknown in the absence of randomized trials, however, if reduction of afternoon phosphorus levels translates into improved cardiovascular outcomes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an analysis of the National Health and Nutrition Examination Survey (NHANES) data, higher dietary phosphorus intake was not associated with mortality risk in moderate CKD [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Although the available literature does not provide evidence that dietary phosphorus restriction results in serum phosphorus level reduction in nondialysis CKD populations, the association between increased serum phosphorus levels and adverse cardiovascular outcomes remains robust.
        </p>
        <p>
         Randomized trials are needed to establish the role of dietary phosphorus restriction in nondialysis CKD patients with eGFR &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         .
        </p>
        <p class="headingAnchor" id="H712938962">
         <span class="h1">
          CARBOHYDRATE AND FAT INTAKE
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest that patients with an estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         who are not undergoing maintenance dialysis consume 25 to 35 kcal/kg/day [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
         Fat should be restricted to &lt;30 percent of daily energy intake, with saturated fat limited to &lt;10 percent energy.
        </p>
        <p>
         Among CKD patients, obesity is associated with the development and progression of cardiovascular events [
         <a href="#rid107">
          107
         </a>
         ] and mortality [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
         Observational studies suggest that higher body mass index (BMI) [
         <a href="#rid109">
          109-111
         </a>
         ] and central adiposity [
         <a href="#rid112">
          112,113
         </a>
         ] are also independent risk factors for progression of CKD and incidence of end-stage kidney disease (ESKD) [
         <a href="#rid108">
          108,114,115
         </a>
         ].
        </p>
        <p>
         The mechanism by which obesity may increase CKD progression is not known. Hemodynamic abnormalities observed in obese individuals include glomerular hyperfiltration [
         <a href="#rid116">
          116
         </a>
         ], increased renal venous pressure [
         <a href="#rid117">
          117
         </a>
         ], and glomerular hypertrophy [
         <a href="#rid118">
          118
         </a>
         ]. Diets that contain excessive fat and carbohydrates are associated with accelerated inflammatory process and oxidative stress in the endothelium, leading to atherosclerosis [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p>
         Weight loss leads to improved blood pressure (BP) control [
         <a href="#rid120">
          120,121
         </a>
         ] and the reduction of hyperfiltration and proteinuria [
         <a href="#rid122">
          122,123
         </a>
         ]. Since hypertension, hyperfiltration, and proteinuria are all risk factors for progression of CKD, this suggests that weight loss in obese CKD patients may slow the progression of kidney disease. Further data to support restriction of excess caloric intake in the CKD population include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High sugar intake and saturated fat intake are associated with albuminuria in cross-sectional studies [
         <a href="#rid124">
          124,125
         </a>
         ]. In one prospective cohort study of Black Americans, a higher consumption of sugar-sweetened beverages was associated with an increased risk of incident CKD [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Nurse's Health Study, a Western dietary pattern characterized by higher intake of processed and red meats, refined grains, sweets, and dessert was associated with greater odds of moderately increased albuminuria (formerly called "microalbuminuria"; odds ratio [OR] 2.17, 95% CI 1.18-3.66) and rapid eGFR decline of ≥3 mL/min/1.73 m
         <sup>
          2
         </sup>
         per year (OR 1.77, 95% CI 1.03-3.03) [
         <a href="#rid127">
          127
         </a>
         ]. By contrast, also in the Nurses' Health Study, a Dietary Approaches to Stop Hypertension (DASH)-style diet (higher intake of fruits, vegetables, legumes, fish, poultry, and whole grains) was not associated with moderately increased albuminuria, but was associated with a lower risk of rapid eGFR decline (OR 0.55, 95% CI 0.38-0.80) [
         <a href="#rid128">
          128
         </a>
         ]. In the same cohort, consumption of two or more servings per day of artificially sweetened soda was independently associated with a twofold higher odds for eGFR decline.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another prospective observational study using the dietary data in the Chronic Renal Insufficiency Cohort (CRIC), greater adherence to several healthy dietary patterns (such as the alternate Mediterranean diet and the DASH diet) was associated with lower risk for CKD progression and all-cause mortality among people with CKD [
         <a href="#rid129">
          129
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective cohort study spanning 15 years demonstrated that doubling of relative energy intake, not BMI, is associated with an increased mortality risk of 48 percent in those with eGFR &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Although data from randomized interventional trials are lacking, avoiding excessive caloric intake might reduce the risk of kidney disease progression and cardiovascular mortality in CKD individuals.
        </p>
        <p class="headingAnchor" id="H712938985">
         <span class="h1">
          RECOMMENDED FIBER INTAKE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The recommended daily dietary fiber intake for CKD patients with estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73 m
         <sup>
          2
         </sup>
         is 14 g per 1000 calories, which is the same as for the general population.
        </p>
        <p>
         Dietary fiber is the nondigestible form of carbohydrates and lignin. Some of the best sources of dietary fiber are beans and peas but also include nuts, fruits, and whole grains. The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.dietaryguidelines.gov%2F&amp;token=o0NKMo%2FctGTsSXqQbfR9ZCoPUmxa9AVvVUQ44Xwkx3zVVopcDSfixk6yFeyp4MDG&amp;TOPIC_ID=7178" target="_blank">
          US Department of Agriculture and US Department of Health and Human Services
         </a>
         , in their updated Dietary Guidelines for Americans 2020-2025, has recommended a daily intake of 14 g per 1000 calories or up to 34 g of fiber for males and 28 g for females.
        </p>
        <p>
         The rationale for the above dietary fiber intake recommendation is based on numerous clinical studies to demonstrate protective effects against cardiovascular disease (CVD), diabetes mellitus, cancer, and all-cause mortality. (See
         <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">
          "Healthy diet in adults"
         </a>
         .)
        </p>
        <p>
         While there are limited data, dietary fiber intake appears to provide similar, if not greater, benefits in the CKD population:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An analysis of National Health and Nutrition Examination Survey (NHANES)-III data (including 14,543 participants and 5.8 percent with eGFR &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         ), showed that, for each 10 g/day higher total fiber intake, the odds of increased serum C-reactive protein was decreased by 38 percent in those with CKD and by 11 percent in those without kidney disease [
         <a href="#rid131">
          131
         </a>
         ]. Furthermore, the dietary fiber intake was inversely correlated with mortality only in those with CKD, suggesting that fiber intake may be more important for individuals with CKD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A six-week study of 13 CKD patients (mean eGFR of 30 mL/min/1.73 m
         <sup>
          2
         </sup>
         ) demonstrated that the addition of fiber (23 g/day) was associated with a significant reduction in serum creatinine by a mean of 0.24 mg/dL (p&lt;0.05) from the baseline value [
         <a href="#rid132">
          132
         </a>
         ]. The change in eGFR corresponded to an increase by approximately 3 mL/min/1.73 m
         <sup>
          2
         </sup>
         from the baseline.
        </p>
        <p>
        </p>
        <p>
         Based on the available data and extrapolating from the general population, therefore, fiber intake is likely protective against CKD progression and mortality, and every effort should be made to encourage higher fiber intake in the CKD population. Because potassium is high in fruits and vegetables, many CKD and dialysis patients are counseled against taking these. This may further compromise dietary fiber intake in the CKD population. However,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.kidney.org%2Fatoz%2Fcontent%2Fpotassium-ckd-diet&amp;token=BeJwjszHx4CzOqdO7Su2QxR4awQGvJRxTrnH0UkfF%2BKeHwkbnn6hNBS2Jg4gBs1BmbpTj434fKPeJQsIJi9T9g%3D%3D&amp;TOPIC_ID=7178" target="_blank">
          fruits and vegetables that are low in potassium
         </a>
         <strong>
         </strong>
         might be consumed in moderation.
        </p>
        <p>
         The overall nutritional recommendations are described in the table  (
         <a class="graphic graphic_table graphicRef105127" href="/z/d/graphic/105127.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1293013800">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">
          "Society guideline links: Chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1193190951">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – The optimal diet for individual chronic kidney disease (CKD) patients varies depending upon the estimated glomerular filtration rate (eGFR), type of kidney disease (ie, proteinuric or nonproteinuric), and the presence of other comorbidities such as hypertension or heart failure. For most CKD patients, the optimal diet is one similar to the Dietary Approaches to Stop Hypertension (DASH) diet, consisting of fruits, vegetables, legumes, fish, poultry, and whole grains. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Overview'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3878.html" rel="external">
          "Diet in the treatment and prevention of hypertension", section on 'Dietary Approaches to Stop Hypertension (DASH) diet'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with eGFR ≥60 mL/min/1.73 m
         </strong>
         <strong>
          <sup>
           2
          </sup>
         </strong>
         <sup>
         </sup>
         – We do not suggest any dietary restriction for patients with eGFR ≥60 mL/min/1.73 m
         <sup>
          2
         </sup>
         . Such patients should follow the same dietary recommendations as for the general population. (See
         <a class="local">
          'Overview'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">
          "Healthy diet in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Protein
         </strong>
         – Among patients with eGFR &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         who are not on dialysis and do not have nephrotic syndrome, we restrict daily protein intake to approximately 0.8 g/kg. A modest protein restriction may slow the progression of CKD and is associated with other benefits including reduced blood urea nitrogen, uremic toxins, decreased acid load, and decreased phosphorus intake. A diet rich in protein from plant sources may be beneficial among CKD patients. (See
         <a class="local">
          'Protein intake'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sodium
         </strong>
         – The optimal dietary salt intake is not known. Our approach is based upon expert opinion, observational studies, and extrapolations from general population studies and depends on the individual patient characteristics:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Among patients with eGFR &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         who have hypertension, volume overload, or increased protein excretion, we restrict sodium intake to &lt;2 g/day.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Among patients with reduced eGFR who do NOT have hypertension, volume overload, or increased protein excretion, we use a more mild sodium restriction to 2.3 g/day. (See
         <a class="local">
          'Salt intake'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Potassium
         </strong>
         – Dietary potassium intake should be individualized based on the serum potassium. In general, potassium restriction is not required until the eGFR decreases to &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         . (See
         <a class="local">
          'Potassium intake'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Calcium
         </strong>
         – Among all patients with eGFR &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         , we limit total calcium intake (both dietary and medication sources) to 1000 mg/day. Data suggest that a diet of 2000 mg/day of calcium in CKD patients may cause a positive calcium balance, with the extra calcium deposited in tissues, leading to metastatic calcification. (See
         <a class="local">
          'Calcium intake'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phosphorus
         </strong>
         – The optimal dietary phosphorus intake is not known. Our approach depends upon the serum phosphorus concentration. Among patients with a normal serum phosphate concentration, we restrict dietary phosphorus intake to 0.8 to 1 g/day. Sources rich in inorganic phosphate, such as highly processed foods, should be avoided as much as possible. (See
         <a class="local">
          'Phosphorus intake'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Caloric intake
         </strong>
         – Among patients with eGFR &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         , we suggest caloric intake of 25 to 35 kcal/kg/day. Higher body mass index (BMI) and central adiposity are independent risk factors for end-stage kidney disease (ESKD), cardiovascular events, and mortality.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Fat should be restricted to &lt;30 percent of daily energy intake, with saturated fat limited to &lt;10 percent energy. (See
         <a class="local">
          'Carbohydrate and fat intake'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fiber
         </strong>
         – The recommended daily dietary fiber intake for CKD patients with eGFR &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         is 5 to 38 g/day, which is the same as for the general population. (See
         <a class="local">
          'Recommended fiber intake'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1556775969">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Ajay K Singh, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164:659.
          </a>
         </li>
         <li class="breakAll">
          http://www.iom.edu/Reports/2013/Sodium-Intake-in-Populations-assessment of Evidence.aspx.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitch WE. Dietary protein restriction in chronic renal failure: nutritional efficacy, compliance, and progression of renal insufficiency. J Am Soc Nephrol 1991; 2:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopple JD, Levey AS, Greene T, et al. Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 52:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walser M, Mitch WE, Maroni BJ, Kopple JD. Should protein intake be restricted in predialysis patients? Kidney Int 1999; 55:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aparicio M, Chauveau P, De Précigout V, et al. Nutrition and outcome on renal replacement therapy of patients with chronic renal failure treated by a supplemented very low protein diet. J Am Soc Nephrol 2000; 11:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernhard J, Beaufrère B, Laville M, Fouque D. Adaptive response to a low-protein diet in predialysis chronic renal failure patients. J Am Soc Nephrol 2001; 12:1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menon V, Kopple JD, Wang X, et al. Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 2009; 53:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikizler TA, Burrowes JD, Byham-Gray LD, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Am J Kidney Dis 2020; 76:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levey AS, Adler S, Caggiula AW, et al. Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis 1996; 27:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levey AS, Greene T, Beck GJ, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol 1999; 10:2426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locatelli F, Alberti D, Graziani G, et al. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet 1991; 337:1299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosman JB, ter Wee PM, Piers-Becht GP, et al. Early protein restriction in chronic renal failure. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985; 21:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002; 62:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosman JB, Langer K, Brandl M, et al. Protein-restricted diets in chronic renal failure: a four year follow-up shows limited indications. Kidney Int Suppl 1989; 27:S96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cianciaruso B, Pota A, Bellizzi V, et al. Effect of a low- versus moderate-protein diet on progression of CKD: follow-up of a randomized controlled trial. Am J Kidney Dis 2009; 54:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evanoff GV, Thompson CS, Brown J, Weinman EJ. The effect of dietary protein restriction on the progression of diabetic nephropathy. A 12-month follow-up. Arch Intern Med 1987; 147:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maschio G, Oldrizzi L, Tessitore N, et al. Effects of dietary protein and phosphorus restriction on the progression of early renal failure. Kidney Int 1982; 22:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitch WE, Walser M, Steinman TI, et al. The effect of a keto acid-amino acid supplement to a restricted diet on the progression of chronic renal failure. N Engl J Med 1984; 311:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeller K, Whittaker E, Sullivan L, et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991; 324:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker JD, Bending JJ, Dodds RA, et al. Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet 1989; 2:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ihle BU, Becker GJ, Whitworth JA, et al. The effect of protein restriction on the progression of renal insufficiency. N Engl J Med 1989; 321:1773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cianciaruso B, Pota A, Pisani A, et al. Metabolic effects of two low protein diets in chronic kidney disease stage 4-5--a randomized controlled trial. Nephrol Dial Transplant 2008; 23:636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Iorio BR, Minutolo R, De Nicola L, et al. Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure. Kidney Int 2003; 64:1822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levey AS, Greene T, Sarnak MJ, et al. Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 2006; 48:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malvy D, Maingourd C, Pengloan J, et al. Effects of severe protein restriction with ketoanalogues in advanced renal failure. J Am Coll Nutr 1999; 18:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams PS, Stevens ME, Fass G, et al. Failure of dietary protein and phosphate restriction to retard the rate of progression of chronic renal failure: a prospective, randomized, controlled trial. Q J Med 1991; 81:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev 2009; :CD001892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fouque D, Laville M, Boissel JP, et al. Controlled low protein diets in chronic renal insufficiency: meta-analysis. BMJ 1992; 304:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fouque D, Wang P, Laville M, Boissel JP. Low protein diets delay end-stage renal disease in non-diabetic adults with chronic renal failure. Nephrol Dial Transplant 2000; 15:1986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 1998; 31:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pedrini MT, Levey AS, Lau J, et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 1996; 124:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fouque D, Aparicio M. Eleven reasons to control the protein intake of patients with chronic kidney disease. Nat Clin Pract Nephrol 2007; 3:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikizler TA. Dietary protein restriction in CKD: the debate continues. Am J Kidney Dis 2009; 53:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams B, Hattersley J, Layward E, Walls J. Metabolic acidosis and skeletal muscle adaptation to low protein diets in chronic uremia. Kidney Int 1991; 40:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gennari FJ, Hood VL, Greene T, et al. Effect of dietary protein intake on serum total CO2 concentration in chronic kidney disease: Modification of Diet in Renal Disease study findings. Clin J Am Soc Nephrol 2006; 1:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaysen GA, Davies RW, Hutchison FN. Effect of dietary protein intake and angiotensin converting enzyme inhibition in Heymann nephritis. Kidney Int Suppl 1989; 27:S154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaysen GA, Jones H Jr, Martin V, Hutchison FN. A low-protein diet restricts albumin synthesis in nephrotic rats. J Clin Invest 1989; 83:1623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi EJ, Bailey J, May RC, et al. Metabolic responses to nephrosis: effect of a low-protein diet. Am J Physiol 1994; 266:F432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maroni BJ, Staffeld C, Young VR, et al. Mechanisms permitting nephrotic patients to achieve nitrogen equilibrium with a protein-restricted diet. J Clin Invest 1997; 99:2479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toeller M, Buyken A, Heitkamp G, et al. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia 1997; 40:1219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nettleton JA, Steffen LM, Palmas W, et al. Associations between microalbuminuria and animal foods, plant foods, and dietary patterns in the Multiethnic Study of Atherosclerosis. Am J Clin Nutr 2008; 87:1825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bach KE, Kelly JT, Palmer SC, et al. Healthy Dietary Patterns and Incidence of CKD: A Meta-Analysis of Cohort Studies. Clin J Am Soc Nephrol 2019; 14:1441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knight EL, Stampfer MJ, Hankinson SE, et al. The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency. Ann Intern Med 2003; 138:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garneata L, Stancu A, Dragomir D, et al. Ketoanalogue-Supplemented Vegetarian Very Low-Protein Diet and CKD Progression. J Am Soc Nephrol 2016; 27:2164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scialla JJ, Appel LJ, Astor BC, et al. Net endogenous acid production is associated with a faster decline in GFR in African Americans. Kidney Int 2012; 82:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raphael KL, Wei G, Baird BC, et al. Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. Kidney Int 2011; 79:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lew QJ, Jafar TH, Koh HW, et al. Red Meat Intake and Risk of ESRD. J Am Soc Nephrol 2017; 28:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haring B, Selvin E, Liang M, et al. Dietary Protein Sources and Risk for Incident Chronic Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Study. J Ren Nutr 2017; 27:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvirdizadeh S, Yuzbashian E, Mirmiran P, et al. A prospective study on total protein, plant protein and animal protein in relation to the risk of incident chronic kidney disease. BMC Nephrol 2020; 21:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel KP, Luo FJ, Plummer NS, et al. The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores. Clin J Am Soc Nephrol 2012; 7:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu IW, Hsu KH, Lee CC, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2011; 26:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motojima M, Hosokawa A, Yamato H, et al. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 2003; 63:1671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994; 124:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun CY, Chang SC, Wu MS. Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS One 2012; 7:e34026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adijiang A, Niwa T. An oral sorbent, AST-120, increases Klotho expression and inhibits cell senescence in the kidney of uremic rats. Am J Nephrol 2010; 31:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moe SM, Zidehsarai MP, Chambers MA, et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scialla JJ, Appel LJ, Astor BC, et al. Estimated net endogenous acid production and serum bicarbonate in African Americans with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:1526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen X, Wei G, Jalili T, et al. The Associations of Plant Protein Intake With All-Cause Mortality in CKD. Am J Kidney Dis 2016; 67:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutiérrez OM, Muntner P, Rizk DV, et al. Dietary patterns and risk of death and progression to ESRD in individuals with CKD: a cohort study. Am J Kidney Dis 2014; 64:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wai SN, Kelly JT, Johnson DW, Campbell KL. Dietary Patterns and Clinical Outcomes in Chronic Kidney Disease: The CKD.QLD Nutrition Study. J Ren Nutr 2017; 27:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell M, Mente A, Rangarajan S, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med 2014; 371:612.
          </a>
         </li>
         <li class="breakAll">
          U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2020-2025. 9th Edition. December 2020. Available at DietaryGuidelines.gov. (Accessed on December 28, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu W, Luying S, Haiyan W, Xiaomei L. Importance and benefits of dietary sodium restriction in the management of chronic kidney disease patients: experience from a single Chinese center. Int Urol Nephrol 2012; 44:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011; 343:d4366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saran R, Padilla RL, Gillespie BW, et al. A Randomized Crossover Trial of Dietary Sodium Restriction in Stage 3-4 CKD. Clin J Am Soc Nephrol 2017; 12:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMahon EJ, Bauer JD, Hawley CM, et al. A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol 2013; 24:2096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meuleman Y, Hoekstra T, Dekker FW, et al. Sodium Restriction in Patients With CKD: A Randomized Controlled Trial of Self-management Support. Am J Kidney Dis 2017; 69:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vegter S, Perna A, Postma MJ, et al. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012; 23:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres VE, Abebe KZ, Schrier RW, et al. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 2017; 91:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He J, Mills KT, Appel LJ, et al. Urinary Sodium and Potassium Excretion and CKD Progression. J Am Soc Nephrol 2016; 27:1202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallamaci F, Leonardis D, Pizzini P, et al. Procalcitonin and the inflammatory response to salt in essential hypertension: a randomized cross-over clinical trial. J Hypertens 2013; 31:1424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graudal NA, Hubeck-Graudal T, Jürgens G. Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens 2012; 25:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev 2013; :CD004937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ 2009; 339:b4567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007; 334:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mills KT, Chen J, Yang W, et al. Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease. JAMA 2016; 315:2200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim H, Caulfield LE, Garcia-Larsen V, et al. Plant-Based Diets and Incident CKD and Kidney Function. Clin J Am Soc Nephrol 2019; 14:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barri YM, Wingo CS. The effects of potassium depletion and supplementation on blood pressure: a clinical review. Am J Med Sci 1997; 314:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hajjar IM, Grim CE, George V, Kotchen TA. Impact of diet on blood pressure and age-related changes in blood pressure in the US population: analysis of NHANES III. Arch Intern Med 2001; 161:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           New SA, Bolton-Smith C, Grubb DA, Reid DM. Nutritional influences on bone mineral density: a cross-sectional study in premenopausal women. Am J Clin Nutr 1997; 65:1831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           New SA, Robins SP, Campbell MK, et al. Dietary influences on bone mass and bone metabolism: further evidence of a positive link between fruit and vegetable consumption and bone health? Am J Clin Nutr 2000; 71:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tucker KL, Hannan MT, Chen H, et al. Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. Am J Clin Nutr 1999; 69:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu K, Devine A, Prince RL. The effects of high potassium consumption on bone mineral density in a prospective cohort study of elderly postmenopausal women. Osteoporos Int 2009; 20:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leonberg-Yoo AK, Tighiouart H, Levey AS, et al. Urine Potassium Excretion, Kidney Failure, and Mortality in CKD. Am J Kidney Dis 2017; 69:341.
          </a>
         </li>
         <li class="breakAll">
          K/DOQI Nutrition in Chronic Renal Failure Guidelines, 2000. Dietary Energy Intake (DEI) for Nondialyzed Patients. https://www.kidney.org/sites/default/files/docs/kdoqi2000nutritiongl.pdf (Accessed on August 31, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barsotti G, Cupisti A, Morelli E, et al. Secondary hyperparathyroidism in severe chronic renal failure is corrected by very-low dietary phosphate intake and calcium carbonate supplementation. Nephron 1998; 79:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int 2012; 81:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int 2017; 92:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; :S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ix JH, De Boer IH, Peralta CA, et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009; 4:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lutsey PL, Alonso A, Selvin E, et al. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study. J Am Heart Assoc 2014; 3:e000936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez-Parra E, Tuñón J, Egido J, Ortiz A. Phosphate: a stealthier killer than previously thought? Cardiovasc Pathol 2012; 21:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez-Parra E, Gonzalez-Casaus ML, Galán A, et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 2011; 26:2567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newsome B, Ix JH, Tighiouart H, et al. Effect of protein restriction on serum and urine phosphate in the modification of diet in renal disease (MDRD) study. Am J Kidney Dis 2013; 61:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menon MC, Ix JH. Dietary phosphorus, serum phosphorus, and cardiovascular disease. Ann N Y Acad Sci 2013; 1301:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murtaugh MA, Filipowicz R, Baird BC, et al. Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III. Nephrol Dial Transplant 2012; 27:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singhal A. Endothelial dysfunction: role in obesity-related disorders and the early origins of CVD. Proc Nutr Soc 2005; 64:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer H, Shoham D, McClure LA, et al. Association of waist circumference and body mass index with all-cause mortality in CKD: The REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis 2011; 58:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer HJ, Saranathan A, Luke A, et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17:1453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005; 46:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans PD, McIntyre NJ, Fluck RJ, et al. Anthropomorphic measurements that include central fat distribution are more closely related with key risk factors than BMI in CKD stage 3. PLoS One 2012; 7:e34699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burton JO, Gray LJ, Webb DR, et al. Association of anthropometric obesity measures with chronic kidney disease risk in a non-diabetic patient population. Nephrol Dial Transplant 2012; 27:1860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iseki K, Ikemiya Y, Kinjo K, et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004; 65:1870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2007; 71:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chagnac A, Weinstein T, Herman M, et al. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003; 14:1480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherney DZ, Sochett EB, Lai V, et al. Renal hyperfiltration and arterial stiffness in humans with uncomplicated type 1 diabetes. Diabetes Care 2010; 33:2068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherney DZ, Scholey JW, Miller JA. Insights into the regulation of renal hemodynamic function in diabetic mellitus. Curr Diabetes Rev 2008; 4:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hennig B, Toborek M, McClain CJ. High-energy diets, fatty acids and endothelial cell function: implications for atherosclerosis. J Am Coll Nutr 2001; 20:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacLaughlin HL, Cook SA, Kariyawasam D, et al. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up. Am J Kidney Dis 2010; 55:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacLaughlin HL, Sarafidis PA, Greenwood SA, et al. Compliance with a structured weight loss program is associated with reduced systolic blood pressure in obese patients with chronic kidney disease. Am J Hypertens 2012; 25:1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ezequiel DG, Costa MB, Chaoubah A, de Paula RB. Weight loss improves renal hemodynamics in patients with metabolic syndrome. J Bras Nefrol 2012; 34:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morales E, Valero MA, León M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daviglus ML, Greenland P, Stamler J, et al. Relation of nutrient intake to microalbuminuria in nondiabetic middle-aged men and women: International Population Study on Macronutrients and Blood Pressure (INTERMAP). Am J Kidney Dis 2005; 45:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riley MD, Dwyer T. Microalbuminuria is positively associated with usual dietary saturated fat intake and negatively associated with usual dietary protein intake in people with insulin-dependent diabetes mellitus. Am J Clin Nutr 1998; 67:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rebholz CM, Young BA, Katz R, et al. Patterns of Beverages Consumed and Risk of Incident Kidney Disease. Clin J Am Soc Nephrol 2019; 14:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin J, Fung TT, Hu FB, Curhan GC. Association of dietary patterns with albuminuria and kidney function decline in older white women: a subgroup analysis from the Nurses' Health Study. Am J Kidney Dis 2011; 57:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin J, Curhan GC. Associations of sugar and artificially sweetened soda with albuminuria and kidney function decline in women. Clin J Am Soc Nephrol 2011; 6:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu EA, Coresh J, Anderson CAM, et al. Adherence to Healthy Dietary Patterns and Risk of CKD Progression and All-Cause Mortality: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis 2021; 77:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iff S, Wong G, Webster AC, et al. Relative energy balance, CKD, and risk of cardiovascular and all-cause mortality. Am J Kidney Dis 2014; 63:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krishnamurthy VM, Wei G, Baird BC, et al. High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int 2012; 81:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salmean YA, Segal MS, Langkamp-Henken B, et al. Foods with added fiber lower serum creatinine levels in patients with chronic kidney disease. J Ren Nutr 2013; 23:e29.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7178 Version 35.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15037495" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15037495" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1751785" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Dietary protein restriction in chronic renal failure: nutritional efficacy, compliance, and progression of renal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9291200" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10027915" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Should protein intake be restricted in predialysis patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10752530" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Nutrition and outcome on renal replacement therapy of patients with chronic renal failure treated by a supplemented very low protein diet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11373349" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Adaptive response to a low-protein diet in predialysis chronic renal failure patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18950911" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32829751" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8629624" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10541304" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1674294" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3887375" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Early protein restriction in chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12081581" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2636680" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Protein-restricted diets in chronic renal failure: a four year follow-up shows limited indications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19800722" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Effect of a low- versus moderate-protein diet on progression of CKD: follow-up of a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3827426" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The effect of dietary protein restriction on the progression of diabetic nephropathy. A 12-month follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7176336" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effects of dietary protein and phosphorus restriction on the progression of early renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6472341" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The effect of a keto acid-amino acid supplement to a restricted diet on the progression of chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1984187" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2574360" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Restriction of dietary protein and progression of renal failure in diabetic nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2512486" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The effect of protein restriction on the progression of renal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17981885" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Metabolic effects of two low protein diets in chronic kidney disease stage 4-5--a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14531817" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8114857" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17162142" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10511331" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Effects of severe protein restriction with ketoanalogues in advanced renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1801057" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Failure of dietary protein and phosphate restriction to retard the rate of progression of chronic renal failure: a prospective, randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19588328" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Low protein diets for chronic kidney disease in non diabetic adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1531426" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Controlled low protein diets in chronic renal insufficiency: meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11096144" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Low protein diets delay end-stage renal disease in non-diabetic adults with chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9631839" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8607590" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17592471" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Eleven reasons to control the protein intake of patients with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19166797" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Dietary protein restriction in CKD: the debate continues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1745030" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Metabolic acidosis and skeletal muscle adaptation to low protein diets in chronic uremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17699190" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Effect of dietary protein intake on serum total CO2 concentration in chronic kidney disease: Modification of Diet in Renal Disease study findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2561514" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Effect of dietary protein intake and angiotensin converting enzyme inhibition in Heymann nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2708523" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A low-protein diet restricts albumin synthesis in nephrotic rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8160792" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Metabolic responses to nephrosis: effect of a low-protein diet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9153292" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Mechanisms permitting nephrotic patients to achieve nitrogen equilibrium with a protein-restricted diet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9349605" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18541574" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Associations between microalbuminuria and animal foods, plant foods, and dietary patterns in the Multiethnic Study of Atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31551237" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Healthy Dietary Patterns and Incidence of CKD: A Meta-Analysis of Cohort Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12639078" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26823552" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Ketoanalogue-Supplemented Vegetarian Very Low-Protein Diet and CKD Progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22475819" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Net endogenous acid production is associated with a faster decline in GFR in African Americans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20962743" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27416946" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Red Meat Intake and Risk of ESRD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28065493" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Dietary Protein Sources and Risk for Incident Chronic Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33203389" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A prospective study on total protein, plant protein and animal protein in relation to the risk of incident chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22490877" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20884620" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12675842" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8035108" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22479508" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19955715" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : An oral sorbent, AST-120, increases Klotho expression and inhibits cell senescence in the kidney of uremic rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21183586" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21700817" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Estimated net endogenous acid production and serum bicarbonate in African Americans with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26687923" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The Associations of Plant Protein Intake With All-Cause Mortality in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24679894" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Dietary patterns and risk of death and progression to ESRD in individuals with CKD: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27939593" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Dietary Patterns and Clinical Outcomes in Chronic Kidney Disease: The CKD.QLD Nutrition Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25119607" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Urinary sodium and potassium excretion, mortality, and cardiovascular events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25119607" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Urinary sodium and potassium excretion, mortality, and cardiovascular events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21603903" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Importance and benefits of dietary sodium restriction in the management of chronic kidney disease patients: experience from a single Chinese center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21791491" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28209636" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A Randomized Crossover Trial of Dietary Sodium Restriction in Stage 3-4 CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24204003" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : A randomized trial of dietary sodium restriction in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27993433" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Sodium Restriction in Patients With CKD: A Randomized Controlled Trial of Self-management Support.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22135311" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Sodium intake, ACE inhibition, and progression to ESRD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27993381" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26382905" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Urinary Sodium and Potassium Excretion and CKD Progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23743803" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Procalcitonin and the inflammatory response to salt in essential hypertension: a randomized cross-over clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22068710" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23633321" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Effect of longer-term modest salt reduction on blood pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19934192" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17449506" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27218629" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31023928" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Plant-Based Diets and Incident CKD and Kidney Function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9216439" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : The effects of potassium depletion and supplementation on blood pressure: a clinical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9099655" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11252120" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Impact of diet on blood pressure and age-related changes in blood pressure in the US population: analysis of NHANES III.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9174480" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Nutritional influences on bone mineral density: a cross-sectional study in premenopausal women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10617959" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Dietary influences on bone mass and bone metabolism: further evidence of a positive link between fruit and vegetable consumption and bone health?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10197575" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18575949" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : The effects of high potassium consumption on bone mineral density in a prospective cohort study of elderly postmenopausal women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27233381" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Urine Potassium Excretion, Kidney Failure, and Mortality in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27233381" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Urine Potassium Excretion, Kidney Failure, and Mortality in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9647491" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Secondary hyperparathyroidism in severe chronic renal failure is corrected by very-low dietary phosphate intake and calcium carbonate supplementation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12081584" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22297674" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28646995" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19644521" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14520607" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17502528" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19211667" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21406649" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21985788" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : FGF23 induces left ventricular hypertrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24922628" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22425627" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Phosphate: a stealthier killer than previously thought?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21436379" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22822075" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Effects of phosphate binders in moderate CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23415016" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Effect of protein restriction on serum and urine phosphate in the modification of diet in renal disease (MDRD) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24117725" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Dietary phosphorus, serum phosphorus, and cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21810769" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15877918" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Endothelial dysfunction: role in obesity-related disorders and the early origins of CVD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21601327" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Association of waist circumference and body mass index with all-cause mortality in CKD: The REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16389251" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Body mass index and risk for end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16597682" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Increasing body mass index and obesity in the incident ESRD population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16253727" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Association between body mass index and CKD in apparently healthy men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22511960" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Anthropomorphic measurements that include central fat distribution are more closely related with key risk factors than BMI in CKD stage 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21965589" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Association of anthropometric obesity measures with chronic kidney disease risk in a non-diabetic patient population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15086929" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Body mass index and the risk of development of end-stage renal disease in a screened cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17136030" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12761248" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : The effects of weight loss on renal function in patients with severe obesity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20585001" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Renal hyperfiltration and arterial stiffness in humans with uncomplicated type 1 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18991597" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Insights into the regulation of renal hemodynamic function in diabetic mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11349944" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : High-energy diets, fatty acids and endothelial cell function: implications for atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19926371" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22717545" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Compliance with a structured weight loss program is associated with reduced systolic blood pressure in obese patients with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22441180" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Weight loss improves renal hemodynamics in patients with metabolic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12552492" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15685502" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Relation of nutrient intake to microalbuminuria in nondiabetic middle-aged men and women: International Population Study on Macronutrients and Blood Pressure (INTERMAP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9440375" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Microalbuminuria is positively associated with usual dietary saturated fat intake and negatively associated with usual dietary protein intake in people with insulin-dependent diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30591520" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Patterns of Beverages Consumed and Risk of Incident Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21251540" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Association of dietary patterns with albuminuria and kidney function decline in older white women: a subgroup analysis from the Nurses' Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20884773" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Associations of sugar and artificially sweetened soda with albuminuria and kidney function decline in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32768632" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Adherence to Healthy Dietary Patterns and Risk of CKD Progression and All-Cause Mortality: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24210588" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Relative energy balance, CKD, and risk of cardiovascular and all-cause mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22012132" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22739658" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Foods with added fiber lower serum creatinine levels in patients with chronic kidney disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
